Table 3

Common variants in MBL2 and odds ratio for being HCV RNA negative among injection drug users

European Americans

African Americans



Locus

Genotype

HCV RNA Negative

%

HCV RNA Positive

%

OR (95% CI)

HCV RNA Negative

%

HCV RNA Positive

%

OR (95% CI)


T-1964C

TT

83

77.6

256

76.0

1.00

82

93.2

288

94.1

1.00

TC

23

21.5

73

21.7

0.94 (0.55–1.60)

6

6.8

17

5.6

1.27 (0.48–3.36)

CC

1

0.9

8

2.4

0.44 (0.05–3.51)

0

0.0

1

0.3

NA

TC + CC

24

22.4

81

24.0

0.91 (0.54–1.53)

6

6.8

18

5.9

1.20 (0.46–3.14)

G-618C (H/L)

CC

44

41.9

124

36.4

1.00

69

80.2

233

76.9

1.00

CG

47

44.8

164

48.1

0.80 (0.50–1.29)

15

17.4

67

22.1

0.76 (0.41–1.42)

GG

14

13.3

53

15.5

0.72 (0.36–1.43)

2

2.2

3

1.0

2.63 (0.42–16.43)

CG + GG

61

58.1

217

63.6

0.80 (0.51–1.26)

17

19.8

70

23.1

0.83 (0.46–1.50)

G-289C (Y/X)

GG

59

55.1

218

66.3

1.00

63

71.6

218

70.6

1.00

GC

42

39.3

103

31.3

1.56 (0.98–2.49)

23

26.1

87

28.2

0.92 (0.53–1.58)

CC

6

5.6

8

2.4

2.72 (0.90–8.23)

2

2.3

4

1.3

2.01 (0.35–11.42)

GC + CC

48

44.9

111

33.7

1.65 (1.05–2.58)

25

28.4

91

29.4

0.97 (0.57–1.63)

T-65C (P/Q)

CC

64

59.8

197

57.4

1.00

21

23.9

64

20.8

1.00

CT

38

35.5

127

37.0

0.93 (0.59–1.48)

43

48.9

160

51.9

0.81 (0.44–1.48)

TT

5

5.0

19

5.5

0.75 (0.27–2.09)

24

27.3

84

27.3

0.85 (0.43–1.67)

CT + TT

43

4.7

146

42.6

0.90 (0.58–1.40)

67

76.1

244

79.2

0.83 (0.47–1.47)

Ex1 C-34T (D)

CC

95

87.2

300

87.5

1.00

87

97.8

303

98.1

1.00

TC

13

11.9

42

12.2

1.06 (0.54–2.10)

2

2.3

6

1.9

1.11 (0.22–5.62)

TT

1

0.9

1

0.3

2.71 (0.16–45.25)

0

0.0

0

0.0

NA

TC + TT

14

12.8

43

12.5

1.00 (0.52–1.91)

2

2.3

6

1.9

1.11 (0.22–5.62)

Ex1 G-27A (B)

GG

85

78.0

256

75.5

1.00

83

93.3

285

93.4

1.00

GA

23

21.1

75

22.1

0.90 (0.53–1.53)

6

6.7

19

6.2

1.10 (0.42–2.86)

AA

1

0.9

8

2.4

0.42 (0.05–3.46)

0

0.0

1

0.3

NA

GA + AA

24

22.0

83

24.5

0.87 (0.52–1.46)

6

6.7

20

6.6

1.04 (0.40–2.70)

Ex1 G-18A (C)

GG

95

92.2

312

96.0

1.00

49

56.3

168

55.6

1.00

GA

8

7.8

13

4.0

2.26 (0.89–5.73)

29

33.3

116

38.4

0.86 (0.51–1.45)

AA

0

0.0

0

0.0

NA

9

10.3

18

6.0

1.68 (0.71–3.99)

GA + AA

8

7.8

13

4.0

2.26 (0.89–5.73)

38

43.7

134

44.4

0.97 (0.60–1.57)

IVS2 G-630A

GG

22

20.8

59

17.9

1.00

49

57.6

168

54.4

1.00

GA

55

51.9

161

48.8

0.89 (0.50–1.59)

31

36.5

127

41.1

0.84 (0.51–1.39)

AA

29

27.4

110

33.3

0.68 (0.36–1.30)

5

5.9

14

4.5

1.22 (0.41–3.60)

GA + AA

84

79.3

271

82.1

0.82 (0.47–1.43)

36

42.4

141

45.6

0.87 (0.54–1.42)

IVS2 T-250C

TT

42

40.4

119

35.6

1.00

72

80.9

236

76.9

1.00

TC

48

46.2

161

48.2

0.84 (0.52–1.36)

15

16.9

68

22.2

0.73 (0.39–1.36)

CC

14

13.5

54

16.2

0.72 (0.36–1.43)

2

2.3

3

1.0

2.52 (0.40–15.75)

TC + CC

62

59.6

215

64.4

0.83 (0.53–1.31)

17

19.1

71

23.1

0.79 (0.44–1.43)

IVS3 G-28C

GG

72

66.7

239

70.7

1.00

36

41.9

135

43.8

1.00

GC

34

31.5

93

27.5

1.28 (0.79–2.07)

39

45.3

144

46.8

1.02 (0.61–1.70)

CC

2

1.9

6

1.8

0.98 (0.19–5.00)

11

12.8

29

9.4

1.42 (0.65–3.14)

GC +CC

36

33.3

99

29.3

1.25 (0.78–1.99)

50

58.1

173

56.2

1.08 (0.66–1.76)

Ex4 C+5G

GG

70

66.7

244

71.6

1.00

41

46.1

143

46.6

1.00

GC

33

31.4

92

27.0

1.31 (0.81–2.14)

39

43.8

138

45.0

0.98 (0.60–1.62)

CC

2

1.9

5

1.5

1.17 (0.22–6.27)

9

10.1

26

8.5

1.22 (0.53–2.82)

GC + CC

35

33.3

97

28.4

1.32 (0.82–2.11)

48

53.9

164

53.4

1.02 (0.63–1.64)

Ex4 T-1483C

TT

65

60.2

193

58.5

1.00

25

28.7

88

29.6

1.00

TC

36

33.3

117

35.5

0.91 (0.57–1.47)

32

36.8

155

52.2

0.72 (0.40–1.30)

CC

7

6.5

20

6.1

1.13 (0.45–2.83)

30

34.5

54

18.2

2.02 (1.07–3.81)

TC + CC

43

39.8

137

41.5

0.94 (0.60–1.47)

62

71.3

209

70.4

1.05 (0.62–1.79)

Ex4 G-1067A

GG

18

17.5

46

13.8

1.00

62

72.9

199

65.9

1.00

GA

48

46.6

156

46.8

0.72 (0.38–1.37)

19

22.4

92

30.5

0.67 (0.38–1.20)

AA

37

35.9

131

39.3

0.65 (0.33–1.26)

4

4.7

11

3.6

1.31 (0.40–4.32)

GA +AA

85

82.5

287

86.2

0.70 (0.38–1.28)

23

27.1

103

34.1

0.73 (0.43–1.25)

Ex4 G-901A

AA

61

58.1

187

57.0

1.00

26

29.2

90

29.8

1.00

GA

37

35.2

118

36.0

0.97 (0.60–1.55)

35

39.3

160

53.0

0.75 (0.42–1.33)

GG

7

6.7

23

7.0

1.02 (0.41–2.52)

28

31.5

52

17.2

1.87 (0.99–3.53)

GA + GG

44

41.9

141

43.0

0.69 (0.61–1.51)

63

70.8

212

70.2

1.03 (0.61–1.73)

Ex4 G-710A

AA

65

60.7

196

58.3

1.00

18

20.2

65

21.3

1.00

GA

34

31.8

120

35.7

0.86 (0.54–1.39)

34

38.2

150

49.2

0.82 (0.43–1.56)

GG

8

7.5

20

6.0

1.31 (0.55–3.17)

37

41.6

90

29.5

1.50 (0.78–2.88)

GA + GG

42

39.3

140

41.7

0.92 (0.59–1.44)

71

79.8

240

78.7

1.07 (0.60–1.93)


NOTE: The most frequent homozygotes among controls served as the referent. Genotypic odds ratios were adjusted for sex, duration of injection drug use, and HIV-serostatus; OR (odds ratio); 95% CI (confidence interval); and NA, not applicable.

Brown et al. BMC Infectious Diseases 2008 8:57   doi:10.1186/1471-2334-8-57

Open Data